CD34+ Cell Culture for High-Yield T Cell Progenitor Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing T cell progenitors are inefficient, and there is a need for high-yield production techniques to address the damage to the thymic microenvironment caused by chemotherapy or chemoradiotherapy in hematopoietic stem cell transplantation, which delays the recovery of peripheral CD4+ and CD8+ T cells.
Innovation Solution
A method involving the culture of CD34+ cells, specifically CD34+/CD43-/CD184-/CD73- cells, in the presence of an aryl hydrocarbon receptor antagonist (SR1) and an LSD1 degradation inducer (UM171), optionally with fibronectin or Delta-like 4 (DLL4), and cytokines like SCF, IL-3, and IL-6, to enhance T cell progenitor differentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to produce T cell progenitors, then the production process is simple, but the production efficiency and yield are low
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including specific cytokine concentrations (SCF, IL-3, IL-6), adding small molecule compounds (SR1, UM171), and controlling culture duration to achieve high-yield T cell progenitor production from CD34+ cells
Solution Approach 2:
The patent uses a composite culture system combining multiple cytokines (SCF, IL-3, IL-6), small molecule compounds (SR1 as AHR antagonist, UM171 as LSD1 degradation inducer), and extracellular matrix components (fibronectin, DLL4) to create a synergistic environment for T cell progenitor differentiation
2Reliability
If chemotherapy or chemoradiotherapy is administered to prepare patients for hematopoietic stem cell transplantation, then the thymic microenvironment is damaged, but the treatment is necessary to eliminate malignant cells
Solution Approach 1:
The patent applies preliminary action by producing T cell progenitors in advance through optimized culture methods, which can then be infused to accelerate thymic recovery after chemotherapy-induced damage, preventing the delay in T cell rearrangement
Solution Approach 2:
The patent converts the harmful effect of chemotherapy (thymic damage) into an opportunity to administer ex vivo-expanded T cell progenitors that can repopulate the thymus and accelerate immune recovery, turning the treatment-induced damage into a pathway for enhanced therapeutic intervention
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the high-efficiency production of T cell progenitors, which can be used in therapeutic agents for cancer and promote thymus recovery post-transplantation, enhancing the immune system's resilience against opportunistic infections.
Implementation Method 1
culturing a cell population containing a CD34 +[0013] The present invention enables the production of a cell population containing T cell progenitors from a cell population containing CD34 +
Implementation Method 2
an LSD1 degradation inducer (UM171)
Implementation Method 3
cytokines like SCF, IL-3, and IL-6, to enhance T cell progenitor differentiation
Implementation Method 4
optionally with fibronectin or Delta-like 4 (DLL4)
Data Source
Figure 1
Figure 2
Figure 3-1
AI summary
Disclosed are a method for producing a cell population containing a T cell progenitor, the method comprising the following step: (1) culturing a cell population containing a CD34+ cell in the presence of an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer, as well as a cell population containing a T cell progenitor obtained by the method, a medicine comprising the cell population containing a T cell progenitor, and a T cell progenitor inducer comprising an aryl hydrocarbon receptor antagonist and an LSD1 degradation inducer.